开窗Anaconda覆膜支架用于复杂主动脉瘤修复的中期结局:一项大型单中心回顾性研究
本研究为单中心回顾性研究,纳入2019年1月至2024年5月连续接受开窗Anaconda覆膜支架治疗的210例复杂腹主动脉及胸腹主动脉瘤患者。技术成功率为96.2%(202/210),手术相关死亡率为2.9%(6/210),主要不良事件发生率为6.2%(13/210)。中期随访显示靶血管不稳定性低,囊袋演变满意,再次干预需求可接受,作者认为需细致的影像学随访。
要点
- 技术成功率96.2%(202/210),手术相关死亡率2.9%(6/210),主要不良事件发生率6.2%(13/210)。
- 随访期间靶血管一期通畅率97.1%(8792/816),二期通畅率98.0%(800/816),无Ia型内漏发生。
- AAA相关再次干预率18.6%,1年、3年、5年免于靶血管不稳定性分别为95.5%、92.5%、91.7%。
核心结论
- 使用开窗Anaconda覆膜支架行复杂腹主动脉或胸腹主动脉瘤腔内修复安全有效,技术成功率高且手术相关死亡率低。
- 中期结果在囊袋演变方面似乎令人满意,靶血管不稳定性发生率低;再次干预需求可接受,作者认为需要细致的影像学随访。
研究设计与样本
- 本研究为单中心回顾性研究,连续纳入2019年1月至2024年5月接受开窗Anaconda覆膜支架治疗的所有患者,共210例。
主要发现
- 平均AAA直径为60.4 ± 9.4 mm,每例患者平均3.9 ± 0.6个开窗,共计816根靶血管。
- 技术成功率为96.2%(202/210),主要不良事件发生率为6.2%(13/210),手术相关死亡率为2.9%(6/210)。
- 平均随访24.0 ± 18.3个月,18.6%的患者需要AAA相关再次干预。
- 随访期间靶血管一期通畅率为97.1%(8792/816),二期通畅率为98.0%(800/816)。
- 1年、3年、5年免于靶血管不稳定性分别为95.5%(95%CI 93.9-97.1%)、92.5%(95%CI 90.2-94.8%)、91.7%(95%CI 89.0-94.4%);随访期间未观察到Ia型内漏。
临床怎么用
- 采用开窗Anaconda覆膜支架行复杂腹主动脉或胸腹主动脉瘤腔内修复安全有效,技术成功率高且手术相关死亡率低。
- 中期囊袋演变结果似乎满意,靶血管不稳定性发生率低;再次干预需求可接受,作者认为需要细致的影像学随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the short and midterm outcomes of the Anaconda fenestrated stent graft for the treatment of complex abdominal and thoraco-abdominal aneurysms. METHODS: This was a retrospective study in a single academic centre. All patients treated consecutively with a fenestrated Anaconda device between January 2019 and May 2024 were included. Outcomes analysed included technical success (TS), procedure related death, occurrence of major adverse events (MAEs) and target vessel instability (TVI), type Ia endoleak (T1aEL), abdominal aortic aneurysm (AAA) related re-interventions, sac changes, and death. RESULTS: Two hundred and ten patients were treated with the Anaconda stent graft. The mean AAA diameter was 60.4 ± 9.4 mm, with a mean of 3.9 ± 0.6 fenestrations per patient for a total of 816 target vessels (TVs). TS was 96.2% (202/210), MAEs occurred in 6.2% of patients (13/210), and procedure related death was 2.9% (6/210). The mean follow up was 24.0 ± 18.3 months. AAA related re-intervention was necessary in 18.6% of patients. Primary and secondary TV patency at follow up were 97.1% (8792/816) and 98.0% (800/816), respectively Freedom from TVI at one, three, and five years was 95.5% (95% confidence interval [CI] 93.9 - 97.1%), 92.5% (95% CI 90.2 - 94.8%), and 91.7% (95% CI 89.0 - 94.4%), respectively. No T1aELs were observed during follow up. Estimated freedom from sac enlargement at one, three, and four years was 96.9% (95% CI 94.3 - 99.6%), 88.4% (95% CI 82.6 - 94.3%), and 82.8% (95% CI 74.1 - 91.6%), respectively. Estimated overall survival at one, three, and five years was 92.2% (95% CI 88.6 - 95.9%), 80.0% (95% CI 73.3 - 86.8%), and 71.6% (95% CI 62.1 - 81.0%), respectively, with one case (0.5%) of late aortic related death. CONCLUSION: Endovascular repair of complex abdominal or thoraco-abdominal aneurysms using the fenestrated Anaconda stent graft is safe and effective with a high TS and low procedure related mortality rate. The midterm results appear satisfactory in terms of sac evolution, with a low TVI rate. The need for re-intervention is acceptable and justifies the need for meticulous imaging follow up.
引用
- Bordet M, Alkhani M, Della-Schiava N, et al. Midterm Outcomes of the Fenestrated Anaconda Stent Graft for Complex Aortic Aneurysm Repair: A Large, Single Centre, Retrospective Study. Eur J Vasc Endovasc Surg. 2025. PMID: 40164379. doi:10.1016/j.ejvs.2025.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。